The Experts below are selected from a list of 14343 Experts worldwide ranked by ideXlab platform
Raoul Kopelman - One of the best experts on this subject based on the ideXlab platform.
-
targeted gold nanoparticles enable molecular ct Imaging of cancer
Nano Letters, 2008Co-Authors: Rachela Popovtzer, Ashish Agrawal, Nicholas A Kotov, Aron Popovtzer, James M Balter, Thomas E Carey, Raoul KopelmanAbstract:X-ray based computed tomography (CT) is among the most convenient Imaging/diagnostic tools in hospitals today in terms of availability, efficiency, and cost. However, in contrast to magnetic resonance Imaging (MRI) and various Nuclear Medicine Imaging modalities, CT is not considered a molecular Imaging modality since targeted and molecularly specific contrast agents have not yet been developed. Here we describe a targeted molecular Imaging platform that enables, for the first time, cancer detection at the cellular and molecular level with standard clinical CT. The method is based on gold nanoprobes that selectively and sensitively target tumor selective antigens while inducing distinct contrast in CT Imaging (increased X-ray attenuation). We present an in vitro proof of principle demonstration for head and neck cancer, showing that the attenuation coefficient for the molecularly targeted cells is over 5 times higher than for identical but untargeted cancer cells or for normal cells. We expect this novel ...
-
targeted gold nanoparticles enable molecular ct Imaging of cancer
Nano Letters, 2008Co-Authors: Rachela Popovtzer, Ashish Agrawal, Nicholas A Kotov, Aron Popovtzer, James M Balter, Thomas E Carey, Raoul KopelmanAbstract:X-ray based computed tomography (CT) is among the most convenient Imaging/diagnostic tools in hospitals today in terms of availability, efficiency, and cost. However, in contrast to magnetic resonance Imaging (MRI) and various Nuclear Medicine Imaging modalities, CT is not considered a molecular Imaging modality since targeted and molecularly specific contrast agents have not yet been developed. Here we describe a targeted molecular Imaging platform that enables, for the first time, cancer detection at the cellular and molecular level with standard clinical CT. The method is based on gold nanoprobes that selectively and sensitively target tumor selective antigens while inducing distinct contrast in CT Imaging (increased X-ray attenuation). We present an in vitro proof of principle demonstration for head and neck cancer, showing that the attenuation coefficient for the molecularly targeted cells is over 5 times higher than for identical but untargeted cancer cells or for normal cells. We expect this novel Imaging tool to lead to significant improvements in cancer therapy due to earlier detection, accurate staging, and microtumor identification.
Rachela Popovtzer - One of the best experts on this subject based on the ideXlab platform.
-
targeted gold nanoparticles enable molecular ct Imaging of cancer
Nano Letters, 2008Co-Authors: Rachela Popovtzer, Ashish Agrawal, Nicholas A Kotov, Aron Popovtzer, James M Balter, Thomas E Carey, Raoul KopelmanAbstract:X-ray based computed tomography (CT) is among the most convenient Imaging/diagnostic tools in hospitals today in terms of availability, efficiency, and cost. However, in contrast to magnetic resonance Imaging (MRI) and various Nuclear Medicine Imaging modalities, CT is not considered a molecular Imaging modality since targeted and molecularly specific contrast agents have not yet been developed. Here we describe a targeted molecular Imaging platform that enables, for the first time, cancer detection at the cellular and molecular level with standard clinical CT. The method is based on gold nanoprobes that selectively and sensitively target tumor selective antigens while inducing distinct contrast in CT Imaging (increased X-ray attenuation). We present an in vitro proof of principle demonstration for head and neck cancer, showing that the attenuation coefficient for the molecularly targeted cells is over 5 times higher than for identical but untargeted cancer cells or for normal cells. We expect this novel ...
-
targeted gold nanoparticles enable molecular ct Imaging of cancer
Nano Letters, 2008Co-Authors: Rachela Popovtzer, Ashish Agrawal, Nicholas A Kotov, Aron Popovtzer, James M Balter, Thomas E Carey, Raoul KopelmanAbstract:X-ray based computed tomography (CT) is among the most convenient Imaging/diagnostic tools in hospitals today in terms of availability, efficiency, and cost. However, in contrast to magnetic resonance Imaging (MRI) and various Nuclear Medicine Imaging modalities, CT is not considered a molecular Imaging modality since targeted and molecularly specific contrast agents have not yet been developed. Here we describe a targeted molecular Imaging platform that enables, for the first time, cancer detection at the cellular and molecular level with standard clinical CT. The method is based on gold nanoprobes that selectively and sensitively target tumor selective antigens while inducing distinct contrast in CT Imaging (increased X-ray attenuation). We present an in vitro proof of principle demonstration for head and neck cancer, showing that the attenuation coefficient for the molecularly targeted cells is over 5 times higher than for identical but untargeted cancer cells or for normal cells. We expect this novel Imaging tool to lead to significant improvements in cancer therapy due to earlier detection, accurate staging, and microtumor identification.
Brian Hutton - One of the best experts on this subject based on the ideXlab platform.
-
the contribution of medical physics to Nuclear Medicine looking back a physicist s perspective
EJNMMI Physics, 2014Co-Authors: Brian HuttonAbstract:Background This paper is the first in a series of invited perspectives by four pioneers of Nuclear Medicine Imaging and physics. A medical physicist and a Nuclear Medicine clinical specialist each take a backward look and a forward look at the contributions of Medical Physics to Nuclear Medicine.
Ralf Bergmann - One of the best experts on this subject based on the ideXlab platform.
-
Evaluation of Brain Nuclear Medicine Imaging Tracers in a Murine Model of Sepsis-Associated Encephalopathy
Molecular Imaging and Biology, 2018Co-Authors: Dávid Szöllősi, Nikolett Hegedűs, Dániel S. Veres, Ildikó Futó, Noémi Kovács, Bernadett Martinecz, Daniel Seifert, Adam Denes, Ildiko Horvath, Ralf BergmannAbstract:Purpose The purpose of this study was to evaluate a set of widely used Nuclear Medicine Imaging agents as possible methods to study the early effects of systemic inflammation on the living brain in a mouse model of sepsis-associated encephalopathy (SAE). The lipopolysaccharide (LPS)-induced murine systemic inflammation model was selected as a model of SAE. Procedures C57BL/6 mice were used. A multimodal Imaging protocol was carried out on each animal 4 h following the intravenous administration of LPS using the following tracers: [^99mTc][2,2-dimethyl-3-[(3E)-3-oxidoiminobutan-2-yl]azanidylpropyl]-[(3E)-3-hydroxyiminobutan-2-yl]azanide ([^99mTc]HMPAO) and ethyl-7-[^125I]iodo-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate ([^125I]iomazenil) to measure brain perfusion and neuronal damage, respectively; 2-deoxy-2-[^18F]fluoro- d -glucose ([^18F]FDG) to measure cerebral glucose uptake. We assessed microglia activity on another group of mice using 2-[6-chloro-2-(4-[^125I]iodophenyl)-imidazo[1,2-a]pyridin-3-yl]- N -ethyl- N -methyl-acetamide ([^125I]CLINME). Radiotracer uptakes were measured in different brain regions and correlated. Microglia activity was also assessed using immunohistochemistry. Brain glutathione levels were measured to investigate oxidative stress. Results Significantly reduced perfusion values and significantly enhanced [^18F]FDG and [^125I]CLINME uptake was measured in the LPS-treated group. Following perfusion compensation, enhanced [^125I]iomazenil uptake was measured in the LPS-treated group’s hippocampus and cerebellum. In this group, both [^18F]FDG and [^125I]iomazenil uptake showed highly negative correlation to perfusion measured with ([^99mTc]HMPAO uptake in all brain regions. No significant differences were detected in brain glutathione levels between the groups. The CD45 and P2Y12 double-labeling immunohistochemistry showed widespread microglia activation in the LPS-treated group. Conclusions Our results suggest that [^125I]CLINME and [^99mTc]HMPAO SPECT can be used to detect microglia activation and brain hypoperfusion, respectively, in the early phase (4 h post injection) of systemic inflammation. We suspect that the enhancement of [^18F]FDG and [^125I]iomazenil uptake in the LPS-treated group does not necessarily reflect neural hypermetabolism and the lack of neuronal damage. They are most likely caused by processes emerging during neuroinflammation, e.g. , microglia activation and/or immune cell infiltration.
-
evaluation of brain Nuclear Medicine Imaging tracers in a murine model of sepsis associated encephalopathy
Molecular Imaging and Biology, 2018Co-Authors: Dávid Szöllősi, Nikolett Hegedűs, Dániel S. Veres, Ildikó Futó, Noémi Kovács, Bernadett Martinecz, Daniel Seifert, Adam Denes, Ildiko Horvath, Ralf BergmannAbstract:The purpose of this study was to evaluate a set of widely used Nuclear Medicine Imaging agents as possible methods to study the early effects of systemic inflammation on the living brain in a mouse model of sepsis-associated encephalopathy (SAE). The lipopolysaccharide (LPS)-induced murine systemic inflammation model was selected as a model of SAE. C57BL/6 mice were used. A multimodal Imaging protocol was carried out on each animal 4 h following the intravenous administration of LPS using the following tracers: [99mTc][2,2-dimethyl-3-[(3E)-3-oxidoiminobutan-2-yl]azanidylpropyl]-[(3E)-3-hydroxyiminobutan-2-yl]azanide ([99mTc]HMPAO) and ethyl-7-[125I]iodo-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate ([125I]iomazenil) to measure brain perfusion and neuronal damage, respectively; 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) to measure cerebral glucose uptake. We assessed microglia activity on another group of mice using 2-[6-chloro-2-(4-[125I]iodophenyl)-imidazo[1,2-a]pyridin-3-yl]-N-ethyl-N-methyl-acetamide ([125I]CLINME). Radiotracer uptakes were measured in different brain regions and correlated. Microglia activity was also assessed using immunohistochemistry. Brain glutathione levels were measured to investigate oxidative stress. Significantly reduced perfusion values and significantly enhanced [18F]FDG and [125I]CLINME uptake was measured in the LPS-treated group. Following perfusion compensation, enhanced [125I]iomazenil uptake was measured in the LPS-treated group’s hippocampus and cerebellum. In this group, both [18F]FDG and [125I]iomazenil uptake showed highly negative correlation to perfusion measured with ([99mTc]HMPAO uptake in all brain regions. No significant differences were detected in brain glutathione levels between the groups. The CD45 and P2Y12 double-labeling immunohistochemistry showed widespread microglia activation in the LPS-treated group. Our results suggest that [125I]CLINME and [99mTc]HMPAO SPECT can be used to detect microglia activation and brain hypoperfusion, respectively, in the early phase (4 h post injection) of systemic inflammation. We suspect that the enhancement of [18F]FDG and [125I]iomazenil uptake in the LPS-treated group does not necessarily reflect neural hypermetabolism and the lack of neuronal damage. They are most likely caused by processes emerging during neuroinflammation, e.g., microglia activation and/or immune cell infiltration.
Nicholas A Kotov - One of the best experts on this subject based on the ideXlab platform.
-
targeted gold nanoparticles enable molecular ct Imaging of cancer
Nano Letters, 2008Co-Authors: Rachela Popovtzer, Ashish Agrawal, Nicholas A Kotov, Aron Popovtzer, James M Balter, Thomas E Carey, Raoul KopelmanAbstract:X-ray based computed tomography (CT) is among the most convenient Imaging/diagnostic tools in hospitals today in terms of availability, efficiency, and cost. However, in contrast to magnetic resonance Imaging (MRI) and various Nuclear Medicine Imaging modalities, CT is not considered a molecular Imaging modality since targeted and molecularly specific contrast agents have not yet been developed. Here we describe a targeted molecular Imaging platform that enables, for the first time, cancer detection at the cellular and molecular level with standard clinical CT. The method is based on gold nanoprobes that selectively and sensitively target tumor selective antigens while inducing distinct contrast in CT Imaging (increased X-ray attenuation). We present an in vitro proof of principle demonstration for head and neck cancer, showing that the attenuation coefficient for the molecularly targeted cells is over 5 times higher than for identical but untargeted cancer cells or for normal cells. We expect this novel ...
-
targeted gold nanoparticles enable molecular ct Imaging of cancer
Nano Letters, 2008Co-Authors: Rachela Popovtzer, Ashish Agrawal, Nicholas A Kotov, Aron Popovtzer, James M Balter, Thomas E Carey, Raoul KopelmanAbstract:X-ray based computed tomography (CT) is among the most convenient Imaging/diagnostic tools in hospitals today in terms of availability, efficiency, and cost. However, in contrast to magnetic resonance Imaging (MRI) and various Nuclear Medicine Imaging modalities, CT is not considered a molecular Imaging modality since targeted and molecularly specific contrast agents have not yet been developed. Here we describe a targeted molecular Imaging platform that enables, for the first time, cancer detection at the cellular and molecular level with standard clinical CT. The method is based on gold nanoprobes that selectively and sensitively target tumor selective antigens while inducing distinct contrast in CT Imaging (increased X-ray attenuation). We present an in vitro proof of principle demonstration for head and neck cancer, showing that the attenuation coefficient for the molecularly targeted cells is over 5 times higher than for identical but untargeted cancer cells or for normal cells. We expect this novel Imaging tool to lead to significant improvements in cancer therapy due to earlier detection, accurate staging, and microtumor identification.
